Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

220 trials with published results (19%)

Research Maturity

802 completed trials (71% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.7%

64 terminated out of 1132 trials

Success Rate

92.6%

+6.1% vs benchmark

Late-Stage Pipeline

17%

189 trials in Phase 3/4

Results Transparency

27%

220 of 802 completed with results

Key Signals

220 with results93% success64 terminated

Data Visualizations

Phase Distribution

891Total
Not Applicable (396)
Early P 1 (7)
P 1 (171)
P 2 (128)
P 3 (126)
P 4 (63)

Trial Status

Completed802
Unknown106
Recruiting86
Terminated64
Active Not Recruiting31
Withdrawn23

Trial Success Rate

92.6%

Benchmark: 86.5%

Based on 802 completed trials

Clinical Trials (1132)

Showing 20 of 20 trials
NCT04291703Phase 2TerminatedPrimary

STOP-T1D Low-Dose (ATG)

NCT05565248Phase 1Terminated

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

NCT06834568Not ApplicableCompletedPrimary

Tandem Freedom - Feasibility Trial 2

NCT04066959Not ApplicableCompletedPrimary

Improving Diabetes in Emerging Adulthood

NCT06546930Not ApplicableActive Not RecruitingPrimary

Device Use Reimagined Through Education And Mentorship

NCT07211126RecruitingPrimary

The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

NCT05434754Not ApplicableCompletedPrimary

Keeping in Touch (KiT) With Youth as They Transition to Adult Type 1 Diabetes Care

NCT06334133Phase 3RecruitingPrimary

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT07474376Not ApplicableNot Yet Recruiting

Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management

NCT04061746Phase 1Active Not RecruitingPrimary

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

NCT07386340Not ApplicableRecruiting

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

NCT05683990Phase 2Active Not RecruitingPrimary

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

NCT06450730Not ApplicableActive Not RecruitingPrimary

Effectiveness of a Combined mHealth-CBT Psychological Intervention to Improve Psychological Well-Being in Young Patients With T1D

NCT07222137Phase 3RecruitingPrimary

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222332Phase 3RecruitingPrimary

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT05923827Not ApplicableCompletedPrimary

Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

NCT07492992Not Yet RecruitingPrimary

HOME-AHCL: Home-Based Implementation of an Advanced Hybrid Closed-Loop System With Telemonitoring in Type 1 Diabetes

NCT05937321Not ApplicableActive Not RecruitingPrimary

National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring With Data Sharing in Older Adults With Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.

NCT06936280Not ApplicableRecruiting

Type 1 Diabetes and Diabetes Distress

NCT07052292CompletedPrimary

User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes

Scroll to load more

Research Network

Activity Timeline